Search

Objective: Children with growth hormone deficiency (GHD) face multiple challenges that can negatively impact the transition from pediatric to adult endocrinology care. For children with GHD resulting from brain cancer or its treatment, the involvement of oncology care providers and possible disease-related comorbidities add further complexity to this transition., Design: An advisory board of pediatric and adult endocrinologists was convened to help better understand the unique challenges faced by childhood cancer survivors with GHD, and discuss recommendations to optimize continuity of care as these patients proceed to adulthood. Topics included the benefits and risks of growth hormone (GH) therapy in cancer survivors, the importance of initiating GH replacement therapy early in the patient's journey and continuing into adulthood, and the obstacles that can limit an effective transition to adult care for these patients., Results/conclusions: Some identified obstacles included the need to prioritize cancer treatment over treatment for GHD, a lack of patient and oncologist knowledge about the full range of benefits provided by long-term GH administration, concerns about tumor recurrence risk in cancer survivors receiving GH treatment, and suboptimal communication and coordination (e.g., referrals) between care providers, all of which could potentially result in treatment gaps or even complete loss of follow-up during the care transition. Advisors provided recommendations for increasing education for patients and care providers and improving coordination between treatment team members, both of which are intended to help improve continuity of care to maximize the health benefits of GH administration during the critical period when childhood cancer survivors transition into adulthood., Competing Interests: Declaration of competing interest CA served as an advisory board member for Novo Nordisk and Pfizer, an advisor for Tolmar, and a Safety Monitor for OPKO Health. MB served as an occasional advisory board member for Novo Nordisk and Pfizer. DC served as a consultant for Novo Nordisk and Crinetics, Inc. GD served as an advisory board member for Corcept, Novo Nordisk, Pfizer, Recordati, and Strongbridge. MG served on advisory boards for Adrenas, Eton Pharmaceuticals, Neurocrine Biosciences, Novo Nordisk, and Pfizer; is performing clinical trials with Adrenas, Diurnal, Neurocrine Biosciences, Novo Nordisk, and Spruce Biosciences; is a consultant to Crinetics and Spruce Biosciences; is a clinical trial adjudicator for Aeterna Zentaris; has been a member of the data and safety monitoring board for Ascendis; receives royalties from McGraw-Hill and UpToDate; and has been a speaker for Pfizer. NK and RO are employees of Novo Nordisk Inc. BSM is a consultant for Ascendis Pharma, BioMarin, Bristol Myers Squibb, EMD Serono, Endo Pharmaceuticals, Novo Nordisk, Orchard Therapeutics, Pfizer, Provention Bio, and Tolmar and has received research support from Alexion, AbbVie, Aeterna Zentaris, Amgen, Amicus, Lumos Pharma, Lysogene, Novo Nordisk, OPKO Health, Pfizer, Prevail Therapeutics, and Sangamo Therapeutics. HS has received research support from Dexcom, Boehringer-Ingelheim, Novartis, Novo Nordisk, Lilly, Soleno, and Rhythm Pharmaceutical; has participated in advisory boards for Novo Nordisk and Ascendis; and is a current speaker for Novo Nordisk, Ascendis and Rhythm Pharmaceuticals. KCJY has received research grants to Barrow Neurological Institute from Ascendis, Corcept, Crinetics, and Amryt; served as an occasional advisory board member for Novo Nordisk, Ascendis, Sandoz, Corcept, Ipsen, Amryt, Strongbridge, Crinetics, Xeris, and Recordati; and served as an occasional speaker for Recordati, Novo Nordisk, and Corcept., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)